MDXHNasdaqServices-Medical Laboratories
MDxHealth SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 3, 2026
$0.18−0.02 (-11.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
MDxHealth SA revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Tissue-based revenue [Member] | $81.49M | $72.33M | $55.72M | $31.15M | 75.5% | +12.7% |
| Liquid-based revenue [Member] | $26.06M | $17.58M | $14.25M | $5.81M | 24.2% | +48.2% |
| Royalties and other revenues [Member] | $326.00K | $139.00K | $228.00K | $89.00K | 0.3% | +134.5% |
By region
From the segment and revenue-disaggregation notes of MDxHealth's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.